Lopinavir–ritonavir in severe COVID-19

A randomized, controlled, open-label trial of lopinavir–ritonavir in patients with severe COVID-19 suggests no gain for the primary endpoint beyond standard care however shows benefit for a few secondary endpoints.

Currently, there are no powerful antiviral treatments towards the unconventional coronavirus SARS-CoV-2, the purpose of the respiration contamination termed COVID-19. During the outbreak of excessive acute respiration syndrome (SARS) in 2003, in vitro testing identified lopinavir, an HIV aspartate protease inhibitor, to have activity towards this virus.

Cao et al. done a randomized, controlled, open-label trial for lopinavir–ritonavir (ritonavir facilitates to stabilize lopinavir) in 199 hospitalized patients with extreme COVID-19, of whom 99 had been assigned to the treatment group, and 100 received the same old of care. The authors located no gain of lopinavir–ritonavir time to clinical improvement beyond the standard of care, although lopinavir–ritonavir became found to have gain for a few secondary endpoints, the protection of the remedy became confirmed, and destiny trials will affirm the results.

The post Lopinavir–ritonavir in severe COVID-19 appeared first on drugscaps.

source https://www.drugscaps.com/lopinavir-ritonavir-in-severe-covid-19/